Planning and Evaluation

规划与评估

• 批准号: 8335531
• 负责人: MICHAEL V. SEIDEN
• 金额: $ 3.54万
• 依托单位: FOX CHASE CANCER CENTER
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-07-21 至 2014-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8335531
• 关键词: Accountability; Address; Architecture; Area; Award; Biomedical Research; Businesses; Cancer Center; Cancer Center Support Grant; Cancer Science; Caring; Chairperson; Clinical; Clinical Investigator; Collaborations; Comprehensive Cancer Center; Data; Decision Support Systems; Development; Diagnosis; Direct Costs; Doctor of Medicine; Education; Education and Outreach; Effectiveness; Elements; Employee; Ensure; Equilibrium; Evaluation; Extramural Activities; Faculty; Fox Chase Cancer Center; Foxes; Funding; Funding Agency; Future; Goals; Grant; Growth; Growth and Development function; Heart; Human Resources; Individual; Information Resources; Institution; Instruction; Integrated Delivery Systems; Investigation; Knowledge; Leadership; Malignant Neoplasms; Marshal; Measures; Medicine; Mind; Mission; NCI-Designated Cancer Center; Nursing Faculty; Performance; Philadelphia; Prevention; Prevention strategy; Process; Production; Program Development; Quality of Care; Recruitment Activity; Research; Research Infrastructure; Resource Development; Resources; Science; Site Visit; Strategic Planning; Translational Research; Update; Vision; Visit; anticancer research; base; cancer research center director; clinical care; improved; instrumentation; meetings; member; operation; programs; success; survivorship; tool

Fox Chase Cancer Center (FCCC) has a well-established strategic management planning process and formally produced five-year strategic and financial plans since 1985. These result in rolling five-year recruitment, resource development, and implementation plans which, after review by the Center's External Advisory Board, are approved by the Center Board of Directors. As part of the change in Center leadership during the current CCSG cycle, a comprehensive strategic planning process was launched under the direction of Associate CCSG Director for Academics J. Robert Beck, Wl.D. This is discussed fully in this section of the grant as well as in the "Overall Description of the Cancer Center" and "Developmental Funds" sections. The plan incorporates Center mission, vision, and values, as well as 13 Strategic Objectives. Targeted recruitment to each of the five CCSG Research Programs and a balance of individual investigation and team science are Critical Success Factors for the two Discovery Objectives in the Plan. No CCSG funds are requested for this planning effort. CCSG funds are requested for two aspects of our evaluation efforts. First, we seek support for our six external advisory boards, five of which provide review and advice to each of our scientific Programs. The sixth, the President's External Advisory Board, is comprised of national leaders in cancer research and NCI designated Cancer Center directors. These External Advisory Boards have been actively involved in our decisions to reconfigure existing or develop new Shared Facilities. They also provide advice on reconfiguration of existing CCSG Programs as well as the balance of team science and individual investigation. The second request is for partial support for our annual daylong Scientific Retreat where members from all five Programs and our clinical investigators meet and discuss opportunities for translational research as well as a broad-range of cancer-related scientific collaborations.

福克斯·蔡斯癌症中心拥有一套完善的战略管理规划程序，自1985年以来正式制定了五年战略和财务计划。这导致了五年的滚动招聘、资源开发和实施计划，这些计划经中心外部咨询委员会审查后，由中心董事会批准。作为中心领导力变化的一部分 在当前的CCSG周期中，在CCSG副主任的指导下，启动了一项全面的战略规划进程，以供Wl.D.J.Robert Beck学者使用。这一点在赠款的这一部分以及“癌症中心的总体描述”和“发展基金”部分进行了充分的讨论。该计划包含了中心的使命、愿景和价值观，以及13个战略目标。 有针对性地招募五个CCSG研究项目中的每一个项目，以及个人调查和团队科学的平衡是该计划中两个发现目标的关键成功因素。这项规划工作不需要CCSG资金。 CCSG需要资金用于我们评估工作的两个方面。首先，我们为我们的六个外部顾问委员会寻求支持，其中五个委员会为我们的每个科学项目提供审查和建议。第六个是总统的外部咨询委员会，由癌症研究的国家领导者和国家癌症研究所指定的 癌症中心主任。这些外部咨询委员会积极参与了我们重新配置现有或开发新的共享设施的决定。他们还就现有CCSG项目的重新配置以及团队科学和个人调查的平衡提供了建议。第二个请求是为我们一年一度的为期一天的科学务虚会提供部分支持，所有五个项目的成员和我们的临床研究人员将在会上会面，讨论转化研究的机会以及与癌症相关的广泛科学合作。